Lab services company Charles River Laboratories (NYSE:CRL) will be announcing earnings results tomorrow before the bell. Here’s what to expect. Charles River Laboratories beat analysts’ revenue expectations by 2.3% last quarter, reporting revenues of $1.00 billion, down 1.1% year on year. It was a mixed quarter for the company, with a solid beat of analysts’ organic revenue estimates but a miss of analysts’ full-year EPS guidance estimates. Is Charles River Laboratories a buy or sell going into earnings? Read our full analysis here, it’s free. This quarter, analysts are expecting Charles River Laboratories’s revenue to decline 6.9% year on year to $941.3 million, a further deceleration from the 1.7% decrease it recorded in the same quarter last year. Adjusted earnings are expected to come in at $2.07 per share.Charles River Laboratories Total Revenue Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Charles River Laboratories has only missed Wall Street’s revenue estimates once over the last two years, exceeding top-line expectations by 2.2% on average. Looking at Charles River Laboratories’s peers in the drug development inputs & services segment, some have already reported their Q1 results, giving us a hint as to what we can expect. Medpace delivered year-on-year revenue growth of 9.3%, beating analysts’ expectations by 6%, and West Pharmaceutical Services reported flat revenue, topping estimates by 2%. Medpace traded down 2.1% following the results while West Pharmaceutical Services was also down 1.6%. Read our full analysis of Medpace’s results here and West Pharmaceutical Services’s results here. There has been positive sentiment among investors in the drug development inputs & services segment, with share prices up 4.4% on average over the last month. Charles River Laboratories is down 10.9% during the same time and is heading into earnings with an average analyst price target of $155.28 (compared to the current share price of $119.44). Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we’ve identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link. View Comments
Charles River Laboratories (CRL) To Report Earnings Tomorrow: Here Is What To Expect
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...